A study to assess and compare for adverse drug reactions (ADR) of of Parenteral Treprostinil for Pulmonary Arterial Hypertension in pediatrics versus adults population using Real-World Pharmacovigilance Data
Latest Information Update: 24 Dec 2021
Price :
$35 *
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- 24 Dec 2021 New trial record